You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The test, the fourth Zika serological assay available under EUA, qualitatively detects Zika virus IgM antibodies in human serum and plasma.
The University of Illinois team developed the technology with an eye at low-resource settings, including developing nations and rural communities.
Researchers were able to identify a specific protein signature for Zika, opening up the possibility that the signature could could be used to screen for exposure to Zika.
Developers can use the Zika virus samples to ascertain whether their tests can help distinguish Zika infection from similar diseases.
The PCR-based test can simultaneously detect for the Zika virus, all serotypes of the dengue virus, the chikungunya virus, the West Nile virus, and a host gene.
For the three months ended June 30, the point-of-care infectious disease diagnostics firm posted $4.1 million in total revenues, up from $3.3 million in Q2 2016.
The US Food and Drug Administration yesterday granted emergency use authorization to Thermo Fisher Scientific's TaqPath Zika Virus Kit.
The firm, which raised $7.1 million from its IPO last week, is looking to move into geographies where a need for infectious disease tests are already well established, its CEO said.
University of Washington scientists found that by adding a material first isolated from shellfish, they could increase the sensitivity of standard bioassays by up to 1,000 times.
The test detected Zika with sensitivity of 92 percent and specificity as high as 96 percent, making it potentially useful for diagnosing and monitoring the disease.